Bookmark and Share
BioAssay: AID 504348

Counterscreen of A1 inhibitors in HMC1-8 Mcl1 dependent cells Measured in Cell-Based System Using Plate Reader - 2045-03_Inhibitor_Dose_DryPowder_Activity_Set3

The fate of cell survival versus apoptosis is determined by the balance of anti and pro-apoptotic proteins. Expression of activator BH3-only proteins, such as BIM or tBID, leads to downstream caspase activation and apoptosis. A1 can functionally bind to and sequester BIM or tBID. In this assay, the parental control cells do not depend on A1 for survival, but are naturally dependent on a different anti-apoptotic protein (Mcl1) to sequester these anti-apoptotic factors. ..more
_
   
 Tested Compounds
 Tested Compounds
All(27)
 
 
Inactive(11)
 
 
Inconclusive(16)
 
 
 Tested Substances
 Tested Substances
All(27)
 
 
Inactive(11)
 
 
Inconclusive(16)
 
 
 Related BioAssays
 Related BioAssays
AID: 504348
Data Source: Broad Institute (2045-03_Inhibitor_Dose_DryPowder_Activity_Set3)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-02-23
Hold-until Date: 2012-02-23
Modify Date: 2012-02-23

Data Table ( Complete ):           All
Tested Compounds:
Depositor Specified Assays
AIDNameTypeComment
2526Summary of Broad Institute MLPCN A1 Apoptosis ProjectsummarySummary assay
Description:
Keywords: apoptosis, BH3 domain, Bcl2-A1, BIM, caspase, cancer

Primary Collaborator: Todd Golub, Broad Institute, golub@broadinstitute.org

Assay Overview:
The fate of cell survival versus apoptosis is determined by the balance of anti and pro-apoptotic proteins. Expression of activator BH3-only proteins, such as BIM or tBID, leads to downstream caspase activation and apoptosis. A1 can functionally bind to and sequester BIM or tBID. In this assay, the parental control cells do not depend on A1 for survival, but are naturally dependent on a different anti-apoptotic protein (Mcl1) to sequester these anti-apoptotic factors.
Cells expressing low A1 or with Bax-Bak knocked out should not show caspase activation if the compound is A1-specific. This cell line, HMC 1-8, is a human cancer cell line with low levels of A1 expression and is immortalized due to factors other than the anti-apoptotic A1.

Expected Outcome: Compounds that cause caspase activation in this HMC 1-8 low A1 line are most likely not working through A1 inhibition. Compounds causing a robust caspase response in this line are not of further interest.
Protocol
Protocol:

1. Human cancer cell line HMC 1-8 are cultured in 150 mm TC dishes with 30 mls of growth media supplemented with 0.5-1 ug/ml blasticidin in a 37 deg C incubator (5% CO2). Use 30 ml media for a 150 mm dish. Do not let cells go beyond 95% confluency (about 30X10^6 cells per 150 mm dish). Split cells 1 to 6-10 (3-4X10^6 cells) for subsequent passage every other day.

DAY 1 MORNING

2. HMC 1-8 cells grown on T200 mm cell culture flasks are washed once with 1X PBS (Gibco), and digested with 1 ml (or 3 ml) 1X trypsin (CellGro Mediatech) for 1-2 minutes.

3. Add 10 ml complete growth media (RPMI-1640 (Cellgrow Mediatech), 10% heat inactivated FBS (Thermo), 1X penn/strep/glutamine (Gibco)) to the plate, mix cells and break clumps, then transfer the cells to a 50 ml centrifuge tube through a cell strainer (BD Falcon # 352340) to get rid of any clumps. Count the cells, and centrifuge cells at 1000 rpm for 4 minutes.

4. Aspirate off the supernatant, and resuspend the cells in complete media at density of 1X10^5 cells/ml.

5. Plate cells in white 384 well plates (Corning 3570), 30 ul/well (2500 cells/well), with Combi (Thermo) while gently stirring the media.

DAY 2

6. Pin transfer 100 nL of compound to the cells and incubate 37 deg C, 5% CO2 and 95% humidity for 4 hours.

7. Remove the plate from the incubator and cool down to room temperature for 30 minutes.

8. Add 10 ul of 1:1 diluted CaspaseGlo (Promega) (diluted with 50 mM HEPES) to each well with Combi multidrop (Thermo.) Shake the plate on the combi nest for 1 minute. Incubate at room temperature for 1 h.

9. Measure luminescence in Envision (Perkin Elmer), std lum, 0.1s/well
Comment
PRESENCE OF CONTROLS: Neutral control wells (NC; n=132) and positive control wells (PC; n=9) were included on every plate.

EXPECTED OUTCOME: Active compounds result in increasing readout signal.

ACTIVE CONCENTRATION LIMIT:
For each sample, the highest valid tested concentration (Max_Concentration) was determined and the active concentration limit (AC_limit) was set to equal Max_Concentration.

WELL MASKING:
This assay measures caspase activation. At high levels of caspase activation, cell death is expected to occur, decreasing the readout and resulting in bell shaped curves for potent compounds. For this reason, higher concentration data points that showed a decrease following an increase were masked and curves were fit to the increasing portion of the curve only.

NORMALIZATION:
The raw signals of the plate wells were normalized using the 'Stimulators Minus Neutral Controls' method in Genedata Assay Analyzer (v7.0.3):
The median raw signal of the intraplate neutral control wells was set to a normalized activity value of 0.
The median raw signal of the intraplate positive control wells was set to a normalized activity value of 100.
Experimental wells values were scaled to this range.

PATTERN CORRECTION: No plate pattern correction algorithm from Genedata Condoseo (v.7.0.3) was applied.

MEASUREMENT USED TO DETERMINE ACTIVE CONCENTRATION (AC): absACnn, the concentration at which the curve crosses threshold 10.0. 10% was used because the positive control in these experiments, Clofoctol, causes very high levels of caspase activation (15-20x) while as little as 2 fold activation is biologically relevant. Therefore, 10% of the Clofoctol signal was considered a threshold for significant activation. It was necessary to use such a potent control to ensure activity across all cell lines and allow normalization in all experiments.
AC values were calculated using the curve fitting strategies in Genedata Screener Condoseo (7.0.3).
AC values were calculated up to the active concentration limit described for each sample.
pAC was set to equal -1*log10(AC)

PUBCHEM_ACTIVITY_OUTCOME:
Activity_Outcome = 1 (inactive) when:
a) compound shows activity but in a direction opposite to the expected outcome
in these cases, values describing curve fitting parameters (Sinf, S0, Hill Slope, log_AC50, log_AC50_SE) are set to null
b) curve fit is constant where activity is > -30% and < 30% at all tested concentrations, or
c) AC > AC_limit
Activity_Outcome = 2 (active) when:
AC <= AC_limit
Activity_Outcome = 3 (inconclusive) when:
a) Curve fitting strategy resulted in a constant fit with activity >= 30% but <= 70%, or
b) The fit was deemed not valid due to poor fit quality.

PUBCHEM_ACTIVITY_SCORE:
If PUBCHEM_ACTIVITY_OUTCOME = 1 (inactive) or 3 (inconclusive),
then PUBCHEM_ACTIVITY_SCORE = 0
If PUBCHEM_ACTIVITY_OUTCOME = 2 (active)
then PUBCHEM_ACTIVITY_SCORE = (10)(pAC)
Scores relate to AC in this manner:
120 = 1 pM
90 = 1 nM
60 = 1 uM
30 = 1 mM
0 = 1 M
When the active concentration (AC) is calculated to be greater than the highest valid tested concentration (Max_Concentration), the PUBCHEM_ACTIVITY_SCORE is calculated using Max_Concentration as the basis.
When the active concentration (AC) is calculated to be less than the lowest tested concentration, the PUBCHEM_ACTIVITY_SCORE is calculated using the lowest tested concentration as the basis.

Note:
The individual dose data point columns ('Activity_at_xxuM') reported here represent the median of valid (unmasked) replicate observations at each concentration. These values are the inputs to a curve fitting algorithm.
All other data columns represent values which are derived during the curve fitting algorithm; this may sometimes include automatic further masking of some replicate data points.
Occasionally this results in perceived inconsistencies: for example, between the derived 'Maximal_Activity' and the apparent most active data point.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1AbsAC10_Qualifier<, =, or >String
2AbsAC10_uM*The concentration at which the fitted curve passes activity threshold 10.FloatμM
3pAbsAC10_MEqual to -1*log10(AbsAC10).Float
4Hill_SlopeThe slope at AC50Float
5S0_(%)The fitted activity value at zero concentrationFloat%
6Sinf_(%)The fitted activity value at infinite concentrationFloat%
7Num_PointsThe number of data points used to generate the plotInteger
8Max_Activity_(%)The maximum activity value observed, based on mean of replicates per concentrationFloat%
9Max_Activity_Conc_uMThe concentration at which the maximum activity is observedFloatμM
10Max_Concentration_uMMaximum valid test concentrationFloatμM
11Activity_at_0.068uM_(%) (0.068μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
12Activity_at_0.135uM_(%) (0.135μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
13Activity_at_0.26uM_(%) (0.26μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
14Activity_at_0.5uM_(%) (0.5μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
15Activity_at_1uM_(%) (1μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
16Activity_at_2.1uM_(%) (2.1μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
17Activity_at_4.2uM_(%) (4.2μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
18Activity_at_8uM_(%) (8μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
19Activity_at_16uM_(%) (16μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%
20Activity_at_35uM_(%) (35μM**)The average measured activity of all accepted replicates at the specified concentrationFloat%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1 R03 DA028853-01

Data Table (Concise)
PageFrom: